As opções de Teste de Risco Fetal DLE têm como objetivo identificar o risco de gestação
afetada em grávidas de todas as idades.
Os resultados das gestantes submetidas aos testes são comparados aos dados obtidos de uma
população de grávidas brasileiras, com vistas a tornar os testes eficientes na nossa
realidade, evitando comparações com grávidas de países com composição étnica diferente do Brasil
(Europa e Estados Unidos).
São utilizadas combinações de marcadores e escolhidos níveis de corte, que delimitam os
testes positivos, com o objetivo de maximizar a detecção de gestações afetadas e minimizar
tanto a ansiedade provocada por um teste positivo em uma gestação não-afetada quanto o
número de gestantes submetidas a procedimentos invasivos.
O laboratório DLE disponibiliza sua Assessoria Científica, composta por profissionais
preparados, para esclarecer dúvidas técnicas e sobre interpretação de laudos.
Para informações sobre credenciamento, parcerias, materiais para divulgação e ou
coleta clique aqui.
Referências Bibliográficas
1. BIAGIOTTI R, BRIZZI L, PERITI E, D'AGATA A, VANZI E, CARIATI E. First trimester screening for Down's syndrome using
maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. Br J Obstet Gynaecol
105:917-920, 1998.
2. BOGART M, PANDIAN MR, JONES OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal
chromosome abnormalities. Prenatal Diagnosis 7:623-630, 1987.
3. BRAMBATI B, MACINTOSH MC, TEISNER B, MAGUINESS S, SHRIMANKER K, LANZANI A, BONACCHI I, TULUI L, CHARD T, GRUDZINSKAS
JG. Low maternal serum levels of pregnancy associated plasma protein A (PAPP-A) in the first trimester in association
with abnormal fetal karyotype. Br J Obstet Gynaecol 100:324-326, 1993.
4. BRIZOT ML, SNIJDERS RJ, BERSINGER NA, KUHN P, NICOLAIDES KH. Maternal serum pregnancy-associated plasma protein A and
fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 84:918-922,
1994.
5. BRIZOT ML, SNIJDERS RJ, BUTLER J, BERSINGER NA, NICOLAIDES KH. Maternal serum hCG and fetal nuchal translucency
thickness for the prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 102:127-132,
1995.
6. BROCK DJH, BOLTON AE, MONAGHAN JM. Prenatal diagnosis of anencephaly through maternal serum alpha-fetoprotein
measurement. Lancet ii:923, 1973.
7. BROCK DJH, SUTCLIFFE RG. Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. Lancet
ii:197-199,1972.
8. CANICK J, KNIGHT GJ, PALOMAKI GE, HADDOW JE, CUCKLE HS, WALD NJ. Low second trimester maternal serum unconjugated
oestriol in pregnancies with Down's syndrome. Brit J Obstet Gynaecol 95:330-333, 1988.
9. CUCKLE HS, WALD NJ, LINDENBAUM RH. Maternal serum alpha-fetoprotein measurement. A screening test for Down
Syndrome. Lancet i:926-929, 1984.
10. CUCKLE HS. Screening for neural tube defects. Ciba Found Symp 181:253-266, 1994.
11. HINO M, KOKI Y, NISHI S. Nimpu ketsu naka no alpha-fetoprotein. Igaku No Ayumi 82:512, 1972.
12. MERKATZ IR, NITOWSKY HM, MACRI JN, JOHNSON WE. An association between low maternal serum alpha-fetoprotein and
fetal chromosomal abnormalities. Am J Obstet Gynecol 148:886-894, 1984.
13. MILUNSKY A, ALPERT E. Results and benefits of a maternal serum alpha-fetoprotein screening program. JAMA.
252:1438-1442, 1984.
14. NICOLAIDES KH, BRIZOT ML, SNIJDERS RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the
first trimester of pregnancy. Br J Obstet Gynaecol 101:782-786, 1994.
15. NICOLAIDES KH, SEBIRE NJ, SNIJDERS RJM. 11-14 Week Scan: The Diagnosis Of Fetal Abnormalities. Carnforth,
UK: Parthenon Publishing, 1999.
16. NORGAARD-PEDERSEN B, BAGGER P, BANG J, FISCHER-RASMUSSEN W, GAD C, HASCH E, HELKJAER PE, JACOBSEN JC, KJELDSEN J,
KJAERSGAARD E, et al. Maternal-serum-alphafetoprotein screening for fetal malformations in 28 062 pregnancies. A
four-year experience from a low-risk area. Acta Obstet Gynecol Scand 64:511-514, 1985.
17. ORLANDI F, DAMIANI G, HALLAHAN TW, KRANTZ DA, MACRI JN. First-trimester screening for fetal aneuploidy: biochemistry
and nuchal translucency. Ultrasound Obstet Gynecol 10:381-386, 1997.
18. PENROSE LS. The relative effects of paternal and maternal age in mongolism. J Genet 27:219, 1933.
19. SNIJDERS RJ, SUNDBERG K, HOLZGREVE W, HENRY G, NICOLAIDES KH. Maternal age- and gestation-specific risk for trisomy 21.
Ultrasound Obstet Gynecol 13:167-70, 1999.
20. SPENCER K, LIAO AW, SKENTOU H, CICERO S, NICOLAIDES KH. Screening for triploidy by fetal nuchal translucency and
maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20:495-499, 2000.
21. SPENCER K, ONG C, SKENTOU H, LIAO AW, H NICOLAIDES K. Screening for trisomy 13 by fetal nuchal translucency and
maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 20:411-416, 2000.
22. SPENCER K, SOUTER V, TUL N, SNIJDERS R, NICOLAIDES KH. A screening program for trisomy 21 at 10-14 weeks using fetal
nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Ultrasound Obstet Gynecol 13:231-237, 1999.
23. SPENCER K, TUL N, NICOLAIDES KH. Maternal serum free beta-hCG and PAPP-A in fetal sex chromosome defects in the first
trimester. Prenat Diagn 20:390-394, 2000.
24. TUL N, SPENCER K, NOBLE P, CHAN C, NICOLAIDES K. Screening for trisomy 18 by fetal nuchal translucency and maternal
serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 19:1035-1042, 1999.
25. WALD NJ, KENNARD A, HACKSHAW A, MCGUIRE A. Antenatal screening for Down's syndrome. J Med Screen 4:181-246, 1997.
26. WALD NJ, RODECK C, HACKSHAW AK, WALTERS J, CHITTY L, MACKINSON AM; SURUSS RESEARCH GROUP. First and second trimester
antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).
Health Technol Assess 7:1-77, 2003.
27. WALD NJ, WATT HC, HACKSHAW AK. Integrated screening for Down's syndrome on the basis of tests performed during the
first and second trimesters. N Engl J Med 341:461-467, 1999.
28. ZIMMERMANN R, HUCHA A, SAVOLDELLI G, BINKERT F, ACHERMANN J, GRUDZINSKAS JG. Serum parameters and nuchal translucency
in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 103:1009-1014, 1996.
|
